Startups
Tortugas Neuroscience
Develops oral small-molecule medicines for neurological and neuropsychiatric disorders. Its clinical-stage pipeline includes compounds licensed from Eisai and Hansoh for conditions such as focal epilepsy, schizophrenia, tinnitus and reversible encephalopathy. The company is advancing lead candidates through Phase 2 development and announced USD106 million in combined seed and Series A financing in April 2026; the individual round amounts were not disclosed.
Team
Albert RobichaudPresident, Head of R&D and Board Director |
Alfredo FontaniniScientific Advisory Board Member |
Chad BeyerHead of Research |
Chelsea BodenstabHead of People & Experience |
Ethan HoffmannHead of Nonclinical Development & Clinical Pharmacology |
 Jeff GoaterDirector |
Jeff JonasChief Executive Officer and Board Director |
Jim FratesDirector |
John JoseyDirector |
Ken HorneDirector |
Mollie BairdHead of Clinical Development Operations |
Paul WatsonHead of Technical Operations, CMC |
Rachel FedykExecutive Director, Strategic Operations |
Ramzi BenamarChief Financial Officer |
Richard LimDirector |
Steven WitowskiHead of Quality |